Clinical Trial Update: LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety, tolerability, efficacy, and pharmacokinetics of TERN-101 in non-cirrhotic non-alcoholic steatohepatitis (NASH) completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• TERN-101 (TERN-101)

Snippet

Sponsor: Terns, Inc. | Conditions: NASH - Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2022-06-14